Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP | O00591 | 2/20 | 0.66 |
| ▸ | GABRD | O14764 | 2/20 | 0.66 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.66 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.66 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.66 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.66 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.66 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.66 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.66 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.66 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.66 |
| ▸ | GABRE | P78334 | 2/20 | 0.66 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.66 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.66 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.66 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.66 |
| ▸ | LDHA | P00338 | 1/20 | 0.58 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31043801 | 1.00 | GABRP (0.66) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL9508554 | 0.98 | GABRP (0.63) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL5782203 | 0.84 | GABRP (0.52) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL13164026 | 0.83 | GABRP (0.50) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL6627726 | 0.83 | CYP1A2 (0.47) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL5336718 | 0.81 | GABRP (0.63) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL30197143 | 0.81 | NNMT (0.62) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL5009904 | 0.81 | NNMT (0.62) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL19857491 | 0.81 | GABRP (0.63) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL191344 | 0.81 | GABRP (0.48) | GABRPGABRDGABRA1GABRB1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115611857-B | Preparation method of 2-methyl-5- (1-methylpyrrolidine-2-yl) pyridine | 上海伍夫科技有限公司 | 2024-05-31 | — | — | CN | claimed |
| EP-0272903-B1 | PROCESS FOR PRODUCING A POLYARYLENE SULFIDE | Tosoh Corporation (JP) | 1993-07-21 | — | — | EP | claimed |
| CN-122079874-A | Method and device for synthesizing etoricoxib key intermediate MMPE through continuous flow | — | 2026-05-26 | — | — | CN | disclosed |
| US-12503477-B2 | Colony stimulating factor-1 receptor (CSF-1R) inhibitors | GENZYME CORPORATION | 2025-12-23 | — | — | US | disclosed |
| US-20240368150-A1 | BICYCLIC TETRAHYDROAZEPINE DERIVATIVES FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. (US) | 2024-11-07 | — | — | US | disclosed |
| US-20240217991-A1 | COLONY STIMULATING FACTOR-1 RECEPTOR (CSF-1R) INHIBITORS | GENZYME CORPORATION (US) | 2024-07-04 | — | — | US | disclosed |
| CN-115611857-B | Preparation method of 2-methyl-5- (1-methylpyrrolidine-2-yl) pyridine | 上海伍夫科技有限公司 | 2024-05-31 | — | — | CN | disclosed |
| US-20230242546-A1 | SUBSTITUTED PYRIDINES, PYRIDAZINES, PYRIMIDINES, AND 1,2,4-TRIAZINES AS TYK2 INHIBITORS | SUDO BIOSCIENCES LIMITED (GB) | 2023-08-03 | — | — | US | disclosed |
| US-20230183264-A1 | TYK2 INHIBITORS AND USES THEREOF | SUDO BIOSCIENCES LIMITED (GB) | 2023-06-15 | — | — | US | disclosed |
| US-20230174553-A1 | TYK2 INHIBITORS AND USES THEREOF | SUDO BIOSCIENCES LIMITED (GB) | 2023-06-08 | — | — | US | disclosed |
| US-20220396588-A1 | COLONY STIMULATING FACTOR-1 RECEPTOR (CSF-1R) INHIBITORS | GENZYME CORPORATION (US) | 2022-12-15 | — | — | US | disclosed |
| EP-1548015-A1 | NOVEL CRYSTALS | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2005-06-29 | — | — | EP | disclosed |
| US-20050096348-A1 | DPP IV inhibitors | BOEHRINGER MARKUS (CH) | 2005-05-05 | — | — | US | disclosed |
| US-6861440-B2 | DPP IV inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2005-03-01 | — | — | US | disclosed |
| EP-1441719-A1 | N-SUBSTITUTED PYRROLIDIN DERIVATIVES AS DIPEPTIDYL PEPTIDASE IV INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-08-04 | — | — | EP | disclosed |
| US-20030130281-A1 | DPP IV inhibitors | HOFFMAN-LA ROCHE INC. | 2003-07-10 | — | — | US | disclosed |
| WO-2003037327-A1 | N-SUBSTITUTED PYRROLIDIN DERIVATIVES AS DIPEPTIDYL PEPTIDASE IV INHIBITORS | F. HOFFMANN-LA-ROCHE AG (CH) | 2003-05-08 | — | — | WO | disclosed |
| EP-0065825-B1 | PYRIDINE DERIVATIVES AS HISTAMINE H2 ANTAGONISTS | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1985-06-19 | — | — | EP | disclosed |
| US-4389403-A | HYPOTENSIVE AGENTS | BASF AKTIENGESELLSCHAFT (DE) | 1983-06-21 | — | — | US | disclosed |
| EP-0037471-A1 | 1-Aroyl-2-phenylamino-2-imidazolines, their preparation and their pharmaceutical compositions | BASF Aktiengesellschaft (DE) | 1981-10-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242546-A1 | SUBSTITUTED PYRIDINES, PYRIDAZINES, PYRIMIDINES, AND 1,2,4-TRIAZINES AS TYK2 INHIBITORS | TYK2, PDXK, JAK1 | GABRP 3916/4885GABRD 3914/4885GABRA1 2473/4885 |
| US-20230174553-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | GABRP 3031/4885GABRD 2522/4885GABRA1 1670/4885 |
| US-20240217991-A1 | COLONY STIMULATING FACTOR-1 RECEPTOR (CSF-1R) INHIBITORS | CSF1R, CSF3R, IL1RN | GABRP 722/4885GABRD 1651/4885GABRA1 311/4885 |
| US-20240368150-A1 | BICYCLIC TETRAHYDROAZEPINE DERIVATIVES FOR THE TREATMENT OF CANCER | BICRA, BRD4, CNR1 | GABRP 1218/4885GABRD 763/4885GABRA1 326/4885 |
| US-20220396588-A1 | COLONY STIMULATING FACTOR-1 RECEPTOR (CSF-1R) INHIBITORS | CSF1R, CSF3R, IL1RN | GABRP 722/4885GABRD 1651/4885GABRA1 311/4885 |
| US-20230183264-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | GABRP 3031/4885GABRD 2522/4885GABRA1 1670/4885 |
| US-12503477-B2 | Colony stimulating factor-1 receptor (CSF-1R) inhibitors | CSF1R, CSF3R, IL1RN | GABRP 705/4885GABRD 1714/4885GABRA1 276/4885 |
| US-20030130281-A1 | DPP IV inhibitors | DPP4, DPP3, DPP7 | GABRP 1552/4885GABRD 3668/4885GABRA1 3274/4885 |
| US-20050096348-A1 | DPP IV inhibitors | DPP4, DPP3, DPP7 | GABRP 1446/4885GABRD 3303/4885GABRA1 3544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.